Rowan Miller

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A

Chris T. Williamson, Rowan Miller, Helen N. Pemberton et al. · Nature Communications · 2016 · 375 citations · Full text

Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity

Ilirjana Bajrami, Jessica Frankum, Asha Konde et al. · Cancer Research · 2013 · 361 citations · Full text

Engineering, Molecular Biology, Pathology +23

Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Philipp Harter, Alexandra Léary, Domenica Lorusso et al. · Annals of Oncology · 2023 · 316 citations · Full text

Gynecological Surgery, Epithelial Ovarian Cancer, Cancer Recurrence +7

Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group

M.F. Mosele, C. Benedikt Westphalen, A Stenzinger et al. · Annals of Oncology · 2024 · 274 citations · Full text

Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i> - and Non– <i>BRCA1/2</i> -Mutant Cancers

Timothy A. Yap, Rebecca Kristeleit, Vasiliki Michalarea et al. · Cancer Discovery · 2020 · 130 citations · Full text